Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $14.53 in the prior trading day, ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $13.82, down -4.89%. In other words, the price has decreased by -$4.89 from its previous closing price. On the day, 0.84 million shares were traded.
Ratios:
Our goal is to gain a better understanding of SPRY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.74 and its Current Ratio is at 11.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $30.
On February 10, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 20 ’25 when Fitzpatrick Alexander A sold 102,969 shares for $14.10 per share. The transaction valued at 1,451,513 led to the insider holds 89,613 shares of the business.
SAUNDERS BRENT L sold 120,000 shares of SPRY for $1,710,024 on May 20 ’25. The Director now owns 0 shares after completing the transaction at $14.25 per share. On May 20 ’25, another insider, Scott Kathleen D., who serves as the Chief Financial Officer of the company, sold 50,000 shares for $14.10 each. As a result, the insider received 705,165 and left with 7,424 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 13.98 while its Price-to-Book (P/B) ratio in mrq is 5.92.
Stock Price History:
Over the past 52 weeks, SPRY has reached a high of $18.51, while it has fallen to a 52-week low of $7.55. The 50-Day Moving Average of the stock is 0.04%, while the 200-Day Moving Average is calculated to be 4.03%.
Shares Statistics:
A total of 98.13M shares are outstanding, with a floating share count of 54.77M. Insiders hold about 44.24% of the company’s shares, while institutions hold 53.75% stake in the company.
Earnings Estimates
The current assessment of ARS Pharmaceuticals Inc (SPRY) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.32 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.44 and -$1.62 for the fiscal current year, implying an average EPS of -$1.54. EPS for the following year is -$0.71, with 4.0 analysts recommending between -$0.45 and -$1.07.
Revenue Estimates
6 analysts predict $12.92M in revenue for the current quarter. It ranges from a high estimate of $15.5M to a low estimate of $10.5M. As of the current estimate, ARS Pharmaceuticals Inc’s year-ago sales were $500kFor the next quarter, 6 analysts are estimating revenue of $26.91M. There is a high estimate of $39.5M for the next quarter, whereas the lowest estimate is $13M.
A total of 6 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $94.28M, while the lowest revenue estimate was $55.53M, resulting in an average revenue estimate of $74.78M. In the same quarter a year ago, actual revenue was $89.15MBased on 6 analysts’ estimates, the company’s revenue will be $198.42M in the next fiscal year. The high estimate is $248.41M and the low estimate is $117.6M.
